Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 336

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 336
---
 to an agreement and plan of merger, dated as of November 18, 2024. All information disclosed in this Form 10-K for periods prior to the Reincorporation Merger Effective Date relates to the Predecessor, and all information disclosed in this Form 10-K for periods after the Reincorporation Merger Effective Date relates to Channel Therapeutics Corporation, a Nevada corporation. Channel’s principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728, and its telephone number is (732) 514-2636. Channel’s website is www.channeltherapeutics.com. Information contained on, or that can be accessed through, its website is not incorporated by reference into this information statement, and you should not consider information on its website to be part of this information statement. Channel makes available free of charge under the “Investors” section of its website all of its filings with the Securities and Exchange Commission (the “SEC”), including its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on its website as soon as reasonably practicable after Channel electronically files or furnishes, as applicable, the information with the SEC. Implications of Being an Emerging Growth and Smaller Reporting Company Channel qualifies as an “emerging growth company” as defined in the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include:

| • | reduced obligations with respect to financial data; |

| • | an exception from compliance with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”); |

| • | reduced disclosure about its executive compensation arrangements in its periodic reports, proxy statements and registration statements; and |

| • | exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements. |

Channel may take advantage of these provisions for up to five years or such earlier time that Channel no longer qualifies as an emerging growth company. Channel would cease to be an emerging growth company upon the earliest of:

| • | the last day of the fiscal year on which Channel has $1.235 billion or more in annual revenue, |

| • | the date on which Channel becomes a “large accelerated